Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three opioid analgesics—oxycodone, oxymorphone, and tramadol. All three are centrally acting opioids used for the management of moderate to severe pain. Oxycodone and oxymorphone are semi-synthetic opioids that act primarily as agonists at the mu-opioid receptor, leading to analgesia by inhibiting ascending pain pathways in the central nervous system. Tramadol is a synthetic opioid with dual mechanisms; it acts as a weak mu-opioid receptor agonist and also inhibits serotonin and norepinephrine reuptake, contributing additional analgesic effects through modulation of descending inhibitory pain pathways[2][5]. This combination would theoretically provide potent multimodal pain relief but would carry significant risks for additive side effects including respiratory depression, sedation, constipation, dependence, and overdose.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxycodone + oxymorphone + tramadol.